Compare BridgeBio Pharma Inc (BBIO) vs Direxion Daily S&P 500 Bull 3X Shares (SPXL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Direxion Daily S&P 500 Bull 3X Shares — how do they compare? BridgeBio Pharma Inc trades at $84.12 (market cap $16.46B), while Direxion Daily S&P 500 Bull 3X Shares trades at $276.15. Which is the better fit depends on your goals.
| BBIO | SPXL | |
|---|---|---|
Market Cap | $16.46B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $90.17 | $288.04 |
52-Week Low | $44.81 | $170.20 |
Enterprise Value | $18.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
SPXL is trading at $272.66, down 2.34% today, with a bullish technical signal supported by moving averages. The stock faces resistance at $277-$283 while finding support at $270-$264 levels. Recent news highlights ongoing AI-driven market dynamics and earnings season catalysts that could influence S&P 500 performance.
Outlook remains cautiously optimistic with technical strength but requires monitoring of earnings results and market sentiment. Key risks include stretched valuations and potential market volatility during earnings season. The stock's performance remains tied to broader S&P 500 trends and AI sector developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Direxion Daily S&P 500 Bull 3X Shares
SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.
Read more on SPXL →
